Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMER: SBRT with Letrozole and Palbociclib in Metastatic ER+ Breast Cancer
NCT04220476Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2020
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of palbociclib, letrozole in breast cancer, sponsored by Weill Cornell Medicine. Planned start Mar 2020; status: withdrawn.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04220476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220476.